---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-065613"
form_type: "8-K"
ticker: "DSGN"
cik: "0001807120"
company_name: "Design Therapeutics, Inc."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T08:43:17.064230+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Design Therapeutics Q1 net loss $17.7M; cash $229.7M funds into 2029

## Summary
- R&D expenses $15.4M, G&A $5.0M for Q1 2025; net loss $17.7M.
- Cash and securities $229.7M as of March 31, 2025; expected runway into 2029.
- Phase 1 SAD trial ongoing for DT-216P2 (FA); MAD patient study planned mid-2025.
- Favorable Phase 1 data for DT-168 (FECD); Phase 2 biomarker trial planned H2 2025.
- Appointed Chris Storgard, M.D., as Chief Medical Officer in April 2025.

## SEC filing metadata
- accession: 0000950170-25-065613
- form_type: 8-K
- ticker: DSGN
- cik: 0001807120
- company_name: Design Therapeutics, Inc.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1807120/000095017025065613/0000950170-25-065613-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1807120/000095017025065613/dsgn-20250507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-065613
- JSON: https://secwatch.observer/filing/0000950170-25-065613.json
- Plain text: https://secwatch.observer/filing/0000950170-25-065613.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.